Evidence map›Paper›PMID 25156701›Full record

ArticleBiological psychiatry2015

In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5.

Christine DeLorenzo, Nicole DellaGioia, Michael Bloch, Gerard Sanacora, Nabeel Nabulsi, Chadi Abdallah, Jie Yang, Ruofeng Wen, J John Mann, John H Krystal and 3 more

Abstract read
In one paragraph

Article in Biological psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed.

  1. Dynamic alterations in the central glutamatergic status following food and glucose intake:Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Trial
  2. Trial
  3. Trial
  4. Review
  5. In vivo evidence for metabotropic glutamate receptor 5 dysregulation in chronic pain.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  6. Review
  7. (R)-ketamine induces mGluPsychopharmacology · 2025
    Article
  8. Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Quantification of [Current neuropharmacology · 2025
    Article
  13. Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  14. Article
  15. Article
  16. Testing PET-[Imaging neuroscience (Cambridge, Mass.) · 2024
    Article
  17. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christine DeLorenzoDepartments of Psychiatry, Stony Brook University, Stony Brook, New York, New York; Applied Mathematics and Statistics, Stony Brook University, Stony Brook, New York, New York. Electronic address: Christine.DeLorenzo@stonybrookmedicine.edu.
Nicole DellaGioiaDepartment of Psychiatry, Columbia University, New York, New York.
Michael BlochDepartment of Psychiatry, Columbia University, New York, New York; Departments of Biomedical Engineering, Yale University, New Haven; Child Study Center, Yale University, New Haven.
Gerard SanacoraDepartment of Psychiatry, Columbia University, New York, New York.
Nabeel NabulsiDepartments of Psychiatry, Yale University, New Haven.
Chadi AbdallahDepartment of Psychiatry, Columbia University, New York, New York; Departments of Biomedical Engineering, Yale University, New Haven; Clinical Neuroscience Division, National Center for PTSD, West Haven, Connecticut.
Jie YangDepartments of Radiology, Stony Brook University, Stony Brook, New York, New York.
Ruofeng WenDepartments of Preventive Medicine, Stony Brook University, Stony Brook, New York, New York.
J John MannApplied Mathematics and Statistics, Stony Brook University, Stony Brook, New York, New York.
John H KrystalDepartment of Psychiatry, Columbia University, New York, New York; Departments of Biomedical Engineering, Yale University, New Haven; Clinical Neuroscience Division, National Center for PTSD, West Haven, Connecticut.
Ramin V ParseyDepartments of Biomedical Engineering, Stony Brook University, Stony Brook, New York, New York.
Richard E CarsonDepartments of Psychiatry, Yale University, New Haven; Diagnostic Radiology, Yale University, New Haven.
Irina EsterlisDepartment of Psychiatry, Columbia University, New York, New York; Departments of Biomedical Engineering, Yale University, New Haven; Child Study Center, Yale University, New Haven.

Funding

YALE UNIVERSITY CLINICAL AND TRANSLATIONAL SCIENCE AWARD PROGRAMUL1RR024139 · NCRR · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2006 to 2011
$56.8M
Translational Technologies CoreP50AA012870 · NIAAA · YALE UNIVERSITY · PI John H. Krystal · 2001 to 2026
$43.7M
Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
HCV &ALCHOOL-- EPIDEMIOLOGY &HOST-VIRUS CORRELATESR01AA012879 · NIAAA · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI PETERS, MARION G · 2000 to 2004
$1.1M
Longitudinal Structural MRI Study of Adulthood Outcome in Tourette SyndromeK23MH091240 · NIMH · YALE UNIVERSITY · PI BLOCH, MICHAEL H · 2010 to 2014
$902k
Examining The Effect Of Ketamine On Glutamate/Glutamine CyclingK23MH101498 · NIMH · YALE UNIVERSITY · PI ABDALLAH, CHADI · 2013 to 2017
$879k
Role of Beta2-nAChR in Bipolar DisorderK01MH092681 · NIMH · YALE UNIVERSITY · PI ESTERLIS, IRINA · 2011 to 2015
$850k
Characterization of a New Metabotropic Glutamate Receptor Subtype 5 PET LigandK01MH091354 · NIMH · STATE UNIVERSITY NEW YORK STONY BROOK · PI DELORENZO, CHRISTINE · 2011 to 2014
$691k
NCATS NIH HHS UL1 TR000142NCRR NIH HHS UL1 RR024139NCRR NIH HHS UL1RR024139NIAAA NIH HHS 2P50AA012879NIAAA NIH HHS P50 AA012870NIAAA NIH HHS R01 AA012879NIMH NIH HHS K01 MH091354NIMH NIH HHS K01MH091354NIMH NIH HHS K01 MH092681NIMH NIH HHS K01MH092681NIMH NIH HHS K23 MH091240NIMH NIH HHS K23 MH101498
6 · The paper itself

Abstract

backgroundAt subanesthetic doses, ketamine, an N-methyl-D-aspartate glutamate receptor antagonist, increases glutamate release. We imaged the acute effect of ketamine on brain metabotropic glutamatergic receptor subtype 5 with a high-affinity positron emission tomography (PET) ligand [(11)C]ABP688 (E)-3-[2-(6-methyl-2-pyridinyl)ethynyl]-2-cyclohexen-1-one-O-(methyl-11C)oxime, a negative allosteric modulator of the metabotropic glutamatergic receptor subtype 5.

methodsTwo [(11)C]ABP688 PET scans were performed in 10 healthy nonsmoking human volunteers (34 ± 13 years old); the two PET scans were performed on the same day-before (scan 1) and during intravenous ketamine administration (.23 mg/kg over 1 min, then .58 mg/kg over 1 hour; scan 2). The PET data were acquired for 90 min immediately after [(11)C]ABP688 bolus injection. Input functions were obtained through arterial blood sampling with metabolite analysis.

resultsA significant reduction in [(11)C]ABP688 volume of distribution was observed in scan 2 relative to scan 1 of 21.3% ± 21.4%, on average, in the anterior cingulate, medial prefrontal cortex, orbital prefrontal cortex, ventral striatum, parietal lobe, dorsal putamen, dorsal caudate, amygdala, and hippocampus. There was a significant increase in measurements of dissociative state after ketamine initiation (p < .05), which resolved after completion of the scan.

conclusionsThis study provides first evidence that ketamine administration decreases [(11)C]ABP688 binding in vivo in human subjects. The results suggest that [(11)C]ABP688 binding is sensitive to ketamine-induced effects, although the high individual variation in ketamine response requires further examination.

Indexed as

AdultBlood PressureBrainBrain MappingCarbon RadioisotopesExcitatory Amino Acid AntagonistsHeart RateHumansKetamineMental ProcessesNeuropsychological TestsOximesPositron-Emission TomographyPyridinesRadiopharmaceuticalsReceptor, Metabotropic Glutamate 53-(6-methylpyridin-2-ylethynyl)cyclohex-2-enone-O-methyloximeCarbon RadioisotopesExcitatory Amino Acid AntagonistsKetamineOximesPyridinesRadiopharmaceuticalsReceptor, Metabotropic Glutamate 5[(11)C]ABP688BrainGlutamateKetaminemGluR5PET

Identifiers

PMID25156701
PMCPMC4277907

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.